Alzheimer's Drugs, APPlication for Down Syndrome?

Overview

Journal Ageing Res Rev

Specialty Geriatrics

Date 2024 Mar 21

PMID 38513771

Authors

Deborah K Sokol

Debomoy K Lahiri

Affiliations

Soon will be listed here.

Abstract

Accumulation of the amyloid β (Aβ) peptide, derived from Aβ precursor protein (APP), is a trait of Down syndrome (DS), as is early development of dementia that resembles Alzheimer's disease (AD). Treatments for this AD in DS simply do not. New drug therapies for AD, e.g., Lecanemab, are monoclonal antibodies designed to clear amyloid plaques composed of Aβ. The increasingly real ability to target and dispose of Aβ favors the use of these drugs in individuals with AD in DS, and, perhaps as earlier intervention for cognitive impairment. We present pertinent similarities between DS and AD in adult DS subjects, discuss challenges to target APP metabolites, and suggest that recently developed antibody treatments against Aβ may be worth investigating to treat AD in DS.

Citing Articles

The striatum is an early, accurate indicator of amyloid burden using [C]PiB in Down syndrome: comparison of two radiotracers.

McLachlan M, Bettcher B, McVea A, DiFillipo A, Zammit M, LeMerise L medRxiv. 2024; .

PMID: 39677434 PMC: 11643166. DOI: 10.1101/2024.12.04.24318526.

References

Lemere C, Blusztajn J, Yamaguchi H, Wisniewski T, Saido T, Selkoe D . Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996; 3(1):16-32. DOI: 10.1006/nbdi.1996.0003. View

Bouter Y, Liekefeld H, Pichlo S, Westhoff A, Fenn L, Bakrania P . Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer's disease and Down syndrome. Acta Neuropathol. 2022; 143(5):601-603. PMC: 9038931. DOI: 10.1007/s00401-022-02418-3. View

Westmark C, Sokol D, Maloney B, Lahiri D . Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism. Mol Psychiatry. 2016; 21(10):1333-41. PMC: 5580495. DOI: 10.1038/mp.2016.134. View

Rannikmae K, Kalaria R, Greenberg S, Chui H, Schmitt F, Samarasekera N . APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry. 2013; 85(3):300-5. PMC: 4018226. DOI: 10.1136/jnnp-2013-306485. View

de Oliveira L, Faria D . Pharmacological Approaches to the Treatment of Dementia in Down Syndrome: A Systematic Review of Randomized Clinical Studies. Molecules. 2022; 27(10). PMC: 9147973. DOI: 10.3390/molecules27103244. View

Lorenzon N, Musoles-Lleo J, Turrisi F, Gomis-Gonzalez M, de la Torre R, Dierssen M . State-of-the-art therapy for Down syndrome. Dev Med Child Neurol. 2023; 65(7):870-884. DOI: 10.1111/dmcn.15517. View

Granno S, Nixon-Abell J, Berwick D, Tosh J, Heaton G, Almudimeegh S . Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus. Sci Rep. 2019; 9(1):7322. PMC: 6513850. DOI: 10.1038/s41598-019-43820-4. View

Souto D, de Sousa M, Ferreira R, Brandao A, Carrera P, Leite H . What are the barriers and facilitators to participation of people with Down syndrome? A scoping review. Dev Med Child Neurol. 2024; 66(8):1013-1030. DOI: 10.1111/dmcn.15857. View

Hanney M, Prasher V, Williams N, Jones E, Aarsland D, Corbett A . Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379(9815):528-36. DOI: 10.1016/S0140-6736(11)61676-0. View

10.

Sokol D, Lahiri D . Neurodevelopmental disorders and microcephaly: how apoptosis, the cell cycle, tau and amyloid-β precursor protein APPly. Front Mol Neurosci. 2023; 16:1201723. PMC: 10556256. DOI: 10.3389/fnmol.2023.1201723. View

11.

Delabar J, Gomes M, Fructuoso M, Sarrazin N, George N, Fleary-Roberts N . EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model. Eur J Med Chem. 2024; 265:116098. DOI: 10.1016/j.ejmech.2023.116098. View

12.

Becker R, Seeman M, Greig N, Lahiri D . What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. Lancet Psychiatry. 2015; 2(8):756-764. PMC: 5161453. DOI: 10.1016/S2215-0366(15)00214-X. View

13.

Sokol D, Lahiri D . APPlications of amyloid-β precursor protein metabolites in macrocephaly and autism spectrum disorder. Front Mol Neurosci. 2023; 16:1201744. PMC: 10548831. DOI: 10.3389/fnmol.2023.1201744. View

14.

Ryoo S, Cho H, Lee H, Jeong H, Radnaabazar C, Kim Y . Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem. 2007; 104(5):1333-44. DOI: 10.1111/j.1471-4159.2007.05075.x. View

15.

Jurkowski M, Bettio L, Woo E, Patten A, Yau S, Gil-Mohapel J . Beyond the Hippocampus and the SVZ: Adult Neurogenesis Throughout the Brain. Front Cell Neurosci. 2020; 14:576444. PMC: 7550688. DOI: 10.3389/fncel.2020.576444. View

16.

Johannesson M, Sahlin C, Soderberg L, Basun H, Falting J, Moller C . Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease. Mol Cell Neurosci. 2021; 114:103641. DOI: 10.1016/j.mcn.2021.103641. View

17.

Head E, Phelan M, Doran E, Kim R, Poon W, Schmitt F . Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Commun. 2017; 5(1):93. PMC: 5709935. DOI: 10.1186/s40478-017-0499-4. View

18.

Contestabile A, Fila T, Ceccarelli C, Bonasoni P, Bonapace L, Santini D . Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus. 2007; 17(8):665-78. DOI: 10.1002/hipo.20308. View

19.

Teller J, Russo C, Debusk L, Angelini G, Zaccheo D, Dagna-Bricarelli F . Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 1996; 2(1):93-5. DOI: 10.1038/nm0196-93. View

20.

Leverenz J, Raskind M . Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998; 150(2):296-304. DOI: 10.1006/exnr.1997.6777. View